Claims for Patent: 8,071,645

Summary for Patent: 8,071,645

Title:	Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
Abstract:	Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
Inventor(s):	Newell; M. Karen (Colorado Springs, CO), Newell; Evan (Toronto, CA), Villalobos-Menuey; Elizabeth (Colorado Springs, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	10/866,141
Patent Claims:	1. A method for treating multi-drug resistant cancer, comprising administering to a subject having multi-drug resistant cancer a therapeutically effective amount of dichloroacetate or a pharmaceutically acceptable salt thereof, wherein the subject is not administered another anti-cancer agent for treating the multi-drug resistant cancer. 2. The method of claim 1, wherein the subject is a human. 3. The method of claim 1, wherein the cancer is lung cancer. 4. The method of claim 1, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is present as a pharmaceutically acceptable salt. 5. The method of claim 1, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is formulated in a pharmaceutically acceptable carrier. 6. The method of claim 5, wherein the pharmaceutically acceptable carrier is a buffering agent. 7. The method of claim 5, wherein the pharmaceutically acceptable carrier is a preservative. 8. The method of claim 1, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is administered by a route selected from the group consisting of oral, vaginal, rectal, buccal, pulmonary, topical, nasal, transdermal, through parenteral injection or implantation, and surgical administration. 9. The method of claim 8, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is administered by an oral route in a solution. 10. The method of claim 8, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is administered by inhalation. 11. The method of claim 10, wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is in a composition with an aerosol in an inhaler. 12. The method of claim 1, wherein the method involves repeated administration of the dichloroacetate or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, wherein the administration of the dichloroacetate or a pharmaceutically acceptable salt thereof is performed to result in sequential exposure over days. 14. The method of claim 12, wherein the administration of the dichloroacetate or a pharmaceutically acceptable salt thereof is performed to result in sequential exposure over weeks. 15. The method of claim 1 wherein the dichloroacetate or a pharmaceutically acceptable salt thereof is dichloroacetate. 16. A method for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of dichloroacetate or a pharmaceutically acceptable salt thereof, further comprising administering etomoxir to the subject. 17. The method of claim 16, further comprising administering a 2-deoxyglucose compound to the subject, wherein the 2-deoxyglucose compound is 2-deoxy-D-glucose. 18. The method of claim 16, further comprising administering an additional cancer treatment to the subject. 19. The method of claim 18, wherein the additional cancer treatment is one or more chemotherapeutic agents. 20. The method of claim 19, wherein the one or more chemotherapeutic agents and the dichloroacetate or a pharmaceutically acceptable salt thereof are applied as part of the same treatment regimen. 21. The method of claim 18, wherein the additional cancer treatment is radiation. 22. The method of claim 18, wherein the additional cancer treatment is an immunotherapeutic. 23. The method of claim 17, wherein the cancer is selected from the group consisting of biliary tract cancer; bladder cancer; brain cancer; glioblastomas; medulloblastomas; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms; multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms; liver cancer; lung cancer; lymphomas; neuroblastomas, oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; stromal tumors and germ cell tumors; thyroid; and renal cancer. 24. The method of claim 23, wherein the hematological neoplasm is acute lymphocytic leukemia or myelogenous leukemia. 25. The method of claim 23, wherein the intraepithelial neoplasm is Bowen's disease or Paget's disease. 26. The method of claim 23, wherein the lymphoma is Hodgkin's disease or lymphocytic lymphoma. 27. The method of claim 23, wherein the oral cancer is squamous cell carcinoma. 28. The method of claim 23, wherein the ovarian cancer is an ovarian cancer arising from epithelial cells, stromal cells, germ cells, or mesenchymal cells. 29. The method of claim 23, wherein the sarcoma is leiomyosarcoma, rhabdomosarcoma, liposarcoma, fibrosarcoma, or osteosarcoma. 30. The method of claim 23, wherein the skin cancer is melanoma, Kaposi's sarcoma, basocellular cancer, or squamous cell cancer. 31. The method of claim 23, wherein the testicular cancer is a seminoma, non-seminoma, teratoma, or choriocarcinoma. 32. The method of claim 23, wherein the thyroid cancer is thyroid adenocarcinoma or medullar carcinoma. 33. The method of claim 23, wherein the renal cancer is adenocarcinoma or Wilm's tumor. 34. A method for treating cancer comprising administering to a subject having cancer a therapeutically effective amount for treating cancer of a composition of dichloroacetate or a pharmaceutically acceptable salt thereof and one or more chemotherapeutic agents selected from the group consisting of methotrexate, trimetrexate, adriamycin, docetaxel, doxorubicin, 5-fluorouracil, vincristine, vinblastine, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol, tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, acronine, ambamustine, anagrelide, andrographolide, asulacrine, atamestane, atrimustine, axinastatin, azacitidine, caracemide, carbetimer, carboplatin, cisplatin, cis-porphyrin, cladribine, cypemycin, cytarabine, cytostatin, dacarbazine, dacliximab, dactinomycin, daunorubicin hydrochloride, decitabine, doxifluridine, doxorubicin hydrochloride, edatrexate, epirubicin hydrochloride, estramustine, etanidazole, etoposide, finasteride, floxuridine, fluorocitabine, formestane, interferons, levamisole, lonidamine, methotrexate sodium, metoclopramide, metoprine, meturedepa, mifepristone, miltefosine, mirimostim, mitindomide, mitocarcin, mitocromin, mitogillin, mitoguazone, mustard anticancer agent, ormaplatin, osaterone, oxaliplatin, oxaunomycin, oxisuran, plicamycin, talisomycin, tallimustine, tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium, teloxantrone hydrochloride, temoporfin, temozolomide, teniposide, teroxirone, testolactone, tetrachlorodecaoxide, tetrazomine, thaliblastine, thalidomide, vapreotide, vinblastine sulfate, vincristine sulfate, vindesine, and vindesine sulfate, wherein dichloroacetate and said one or more chemotherapeutic agents are the only active agents in the composition.

Details for Patent 8,071,645

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2023-06-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2023-06-12
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2023-06-12